Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: M05BA06

Iasibon(ibandronic acid)

Hypercalcemia;Fractures, Bone;Neoplasm Metastasis;Breast Neoplasms

Marketing Authorisation Holder: Pharmathen S.A.

EMA Authorisation: 21/01/2011

INN: ibandronic acid

Indication

Concentrate for solution for infusion Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. Treatment of tumour-induced hypercalcaemia with or without metastases. Film-coated Tablets Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Iasibon — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.